Common deficiences in abbreviated new durg application Part 2: Description, composition, and excipients

Pharmaceutical Technology

Volumn 34, Issue 8, 2010, Pages 45-51

  Srinivasan, Aloka ^a   Iser, Robert ^a   Gill, Devinder S ^a  

^a Center for Drug Evaluation and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIS OIL; ASPARTAME; BENZYL ALCOHOL; CASTOR OIL; COLORING AGENT; CROSPOVIDONE; IRON OXIDE; MACROGOL; METHACRYLIC ACID; POVIDONE;

BRAIN SPONGIOSIS; DRUG APPROVAL; DRUG MANUFACTURE; DRUG STABILITY; EXCIPIENT COMPATIBILITY; FOOD AND DRUG ADMINISTRATION; REVIEW; SHELF LIFE;

EID: 78651274873     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. A. Srinivasan and R. Iser, Pharm. Technol. 34 (1) 50-59 (2010).
2. FDA, Inactive Ingredient Search for Approved Drug Products, http://www.accessdata.fda.gov/scripts/cder/iig/, accessed June 30, 2010.
3. FDA, Guidance for Industry: Immediate Release Dosage Forms, Scale Up and Post Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequiva lence Documentation (SUPAC IR) (Rockville, MD, Nov. 1995).
4. FDA, QbR Frequently Asked Questions (June 4, 2007).
5. FDA, Guidance for Industry: Submitting Documentation for the Manufacturing of and Controls for Drug Products (Rockville, MD, Feb. 1987).
6. FDA, Data Standards Manual (monographs), Dosage Form, CDER Data Element Number, C DRG 00201 (Dec. 15, 2006)
7. FDA, "21 CFR 314 Applications for FDA Approval to Market a New Drug," [Content and Format of an Abbreviated New Drug Application, Sec. 314.94 (9)].
8. FDA, "Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)"
9. FDA, Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients (Rockville, MD, May 18, 2005).
10. FDA, "21 CFR 73 Listing of Color Additives Exempt from Certi fication", [Synthetic Iron Oxide, Sec. 73.1200].
11. S. Borodkin and M. H. Yunker, Jrnl. of Pharma. Sci. 59(4)481 386 (1970).
12. R. C. Rowe, P.J. Shesky, and M. E. Quinn, Eds., Handbook of Pharmaceutical Excipients, 6th ed. (Pharmaceutical Press, July 31, 2009).
13. USP 32 NF 27 (USP, Rockville, MD, 2010).
14. FDA, "21 CFR 170 Food Additives 21 CFR 180 Food Additives Permitted in Food or in Contact with Food on an Interim Basis Pending Additional Study."
15. Food and Chemicals Codex 6 (USP, Rockville, MD, 2010).
16. IPEC Americas, Excipient Master File Guide (Arlington, VA, 2004).
17. FDA, "21 CFR 211 Current Good Manufacturing Practice for Finished Pharmaceutical," [Testing and Approval or Rejection of Components, Drug Product Containers, and Closures, Sec. 211.84 (d) (2)].